Shots:
- The US FDA has granted ODD to CFT7455 for the treatment of MM. The FDA grants ODD to drugs & biologics that are intended for the safe and effective treatment, diagnosis or prevention of rare diseases, or conditions that affect fewer than 200,000 people in the US
- In Jun’21, the company has initiated a P-I/II clinical trial to evaluates safety, tolerability, and anti-tumor activity of CFT7455 in ~160 patients with secondary and exploratory objectives are to identify the PK and PD of the therapy
- CFT7455 (PO) is a bioavailable MonoDAC degrader targeting IKZF1/3 for the treatment of MM and NHL including peripheral T-cell lymphoma and MCL
Click here to read full press release/ article | Ref: C4 Therapeutics | Image: Analyze Markets
The post C4T’s CFT7455 Receives the US FDA’s Orphan Drug designation for the Treatment of Multiple Myeloma first appeared on PharmaShots.
